SPIRITT (STUDY 20060141): A RANDOMISED PHASE 2 STUDY OF FOLFIRI WITH EITHER PANITUMUMAB (pmab) OR BEVACIZUMAB (bev) AS 2ND-LINE TREATMENT (tx) IN PATIENTS (pts) WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (mCRC)

被引：0
|
作者：
Hecht, J. R. [1 ]
Cohn, A. [2 ]
Dakhil, S. [3 ]
Saleh, M.
Cline-Burkhardt, M. [4 ]
Piperdi, B. [5 ]
Tian, Y. [6 ]
Go, W. [6 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Canc Ctr Kansas, Liberal, KS USA
[4] US Oncol, Austin, TX USA
[5] Montefiore Med Ctr, New York, NY USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [41] Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G
    Shitara, Kohei
    Yonesaka, Kimio
    Denda, Tadamichi
    Yamazaki, Kentaro
    Moriwaki, Toshikazu
    Tsuda, Masahiro
    Takano, Toshimi
    Okuda, Hiroyuki
    Nishina, Tomohiro
    Sakai, Kazuko
    Nishio, Kazuto
    Tokunaga, Shoji
    Yamanaka, Takeharu
    Boku, Narikazu
    Hyodo, Ichinosuke
    Muro, Kei
    CANCER SCIENCE, 2016, 107 (12) : 1843 - 1850
  • [42] Tumor response outcomes in first-line treatment of wild-type (WT) RAS metastatic colorectal carcinoma (mCRC) following modified FOLFOX6 (mFOLFOX6) + either panitumumab (pmab) or bevacizumab (bev).
    Rivera, Fernando
    Karthaus, Meinolf
    Hecht, J. Randolph
    Fasola, Gianpiero
    Canon, Jean-Luc
    Koukakis, Reija
    Terwey, Jan-Henrik
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
    Barry, Garrett
    Li-Chang, Hector Hugo
    Kennecke, Hagen F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [44] Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Barry, Garrett S.
    Cheang, Maggie C.
    Chang, Hector Li
    Kennecke, Hagen F.
    ONCOTARGET, 2016, 7 (14) : 18953 - 18964
  • [45] Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.
    Price, Timothy Jay
    Peeters, Marc
    Kim, Tae Won
    Li, Jin
    Cascinu, Stefano
    Ruff, Paul
    Suresh, Attili Venkatasatya
    Thomas, Anne
    Tjulandin, Sergei
    Zhang, Kathy
    Sidhu, Roger
    Murugappan, Swaminathan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [46] Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining
    Peeters, M.
    Cervantes-Ruiperez, A.
    Strickland, A.
    Ciuleanu, T.
    Mainwaring, P. N.
    Tzekova, V. I.
    Santoro, A.
    Johnson, C. W.
    Zhang, A.
    Gansert, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study
    Chibaudel, B.
    Tournigand, C.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Nguyen, S.
    Bachet, J.
    Aissat, N.
    Blons, H.
    Laurent-Puig, P.
    De Gramont, A.
    Andre, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] A randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Safety and efficacy results.
    Van Cutsem, E.
    Eng, C.
    Tabernero, J.
    Nowara, E.
    Swieboda-Sadlej, A.
    Tebbutt, N. C.
    Mitchell, E. P.
    Davidenko, I.
    Chen, L.
    Smethurst, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [49] Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Lee, Michael Sangmin
    Loehrer, Patrick J.
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen Keon
    Moore, Dominic T.
    Carlson, Cheryl Ann
    Sanoff, Hanna Kelly
    McRee, Autumn Jackson
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [50] Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy - a GERCor Study
    Andre, T.
    Chibaudel, B.
    Mabro, M.
    Bennamoun, M.
    Artru, P.
    Bachet, J. B.
    Hadengue, A.
    Blons, H.
    Laurent-Puig, P.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S435 - S435
12345